Avinger Inc (AVGR) News

AVGR, 10 day hourly chart

By: Tomas Ronolski - AllPennyStocks.com News
Tuesday, December 24, 2024

A California-based healthcare company turned heads during Tuesday’s session after the company’s stock was halted following the U.S. patent award for its ‘Atherectomy Catheter Drive Assemblies’, according to a press release.

Traders were quick to snatch up shares of Avinger Inc. (Nasdaq:AVGR), pushing the micro cap up to $1.93/share (+200.44%) at the early session high. This move was a strong breakout from the multi-month downtrend this stock has been corralled by since May.

Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

This would be a 900 dollars a share if not for phantom shares trading. Tiny float

So ridiculous where the hell are all these shares coming from OS is tiny????

Back to $1.91

moving

I feel bad for buyers. Merry Christmas!

Tax loss sellling

Wow, almost 15x's OS count already traded pre market? So where do all these shares come from?

Good morning Monk. Any idea what’s going on here? Why the surge up?

avgr..........................https://stockcharts.com/h-sc/ui?s=avgr&p=W&b=5&g=0&id=p86431144783

As high as $2.50 at $2 now + 215% 3m floater

Liquidation time .53 

AVGR new 52 week low

AVGR new 52 low

AVGR new 52 week low

Not in currently. Looks to be still searching for it's bottom.

AVGR new 52 week low

AVGR..................................https://stockcharts.com/h-sc/ui?s=AVGR&p=W&b=5&g=0&id=p86431144783

$AVGR aw, there she went.

$AVGR low floater poking it's nose into oversold territory.

AVGR under $2

AVGR new 52 week low

AVGR new 52 week low

AVGR new 52 week low

AVGR 10Q due 3/20

Hello darlin, yep here off and on. Traveling some, hunting, fishing coaching a soccer team.

Good Morning dear man...you still around? jumped back on and it seems the old team is all but gone.

$AVGR that works.

Yup, I may buy a few.

AVGR new 52 week low

AVGR new 52 week low

$AVGR, 1.37 mil O/S.

AVGR new 52 week low

AVGR new 52 week low

I need this to sky rocket to the moon. Come on with a huge announcement please

AVGR new 52 week low

AVGR new 52 week low

AVGR new 52 week low

Snagged more 4s hot 16$ not long ago like 2 weeks

Reloaded 4s and 5 last few days. 💥

Loaded 500 shares at $5.80 come on Rip!

Buy, buy, buy. Buy all you can, OS back to nasdaq standard and funds raised! Squeeze tjme!

Bet this goes bananas 🍌 soon over reatction

Boom 💥

They deserved what they got

Lol

Here come the short sellers

Item 8.01. Other Events

As previously disclosed, on May 20, 2022, Avinger, Inc., (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Shares”), initially up to an aggregate offering price of $7,000,000, from time to time in an at-the-market public offering. On August 3, 2022, the Company determined to suspend sales under the ATM Agreement and terminated the continuous offering of the initial aggregate offering price of $7,000,000. In March 2023, the Company determined to resume sales under the ATM Agreement, up to an aggregate offering price of $1,149,028 and on September 18, 2023, the Company increased the amount available for sale by up to an additional aggregate offering price of $2,133,181.

The Company has determined to increase the amount available for sale under the ATM Agreement, up to an additional aggregate offering price of $1,074,690. The Shares sold under the ATM Agreement will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-263922), which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the at-the-market offering filed with the SEC on September 20, 2023.

Because there is no minimum offering amount required pursuant to the ATM Agreement, the total number of Shares to be sold under the ATM agreement, if any, and proceeds to the Company, if any, are not determinable at this time. The Company expects to use any net proceeds for primarily for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of its sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures. The Company has not yet determined the amount of net proceeds to be used specifically for any particular purpose or the timing of these expenditures. The Company may use a portion of the net proceeds to acquire complementary products, technologies or businesses or to repay principal on its debt; however, it currently has no binding agreements or commitments to complete any such transactions or to make any such principal repayments from the proceeds of this offering, although it does look for such acquisition opportunities. Accordingly, the Company’s management will have significant discretion and flexibility in applying the net proceeds from the sale of these securities

6k at 11.9 wow can’t believe I’m getting so lucky